This study evaluates the effectiveness and safety of surgical aortic valve replacement and transcatheter aortic valve replacement in aortic Stenosis.
All TAVR and SAVR cases will be enrolled retrospectively and prospectively. This registry includes sub group analysis named STRATEGY AS(Role of Sarcopenia and frailTy in pRedicting outcomes After TranscathEter or surGical aortic valve replacement in elderlY patients with Aortic Stenosis: A prospective cohort study). For this sub group analysis, all enrolled subjects will have following tests : EQ-5D, KCCQ-12(Kansas City Cardiomyopathy Questionnaire), ADL(Activities of daily living), IADL(Instrumental. Activities of Daily Living), Nagi \& Rosow-Breslau self-reported items, Previous fall events since 6 months (initial) or last visit(F/U), IPAQ(The International Physical Activity Questionnaires), Social frailty screening, CES-D(Center for Epidemiologic Studies Depression Scale), MNA-SF(Mini Nutritional Assessment - Short Form),SPPB score (Short Physical Performance Battery, usual gait speed, balance, chairstand), Multi-task gait test (counting7, animal, motor, motor\&counting7), Grip strength, Bioimpedance analysis, Muscle tone at thigh and calf, UEF (Upper extremities function).
Study Type
OBSERVATIONAL
Enrollment
900
Asan Medical Hospital
Seoul, South Korea
All cause death
Time frame: 1 year
Cardiovascular mortality
Time frame: 1,6 and 12 months and 5 years
Cardiovascular mortality
Death due to proximate cardiac cause Death caused by noncoronary vascular condition All procedure-related/surgery-related death All valve-related death Sudden or unwitnessed death Death of unknown cause
Time frame: 1,6 and 12 months and 5 years
Myocardial infarction
Time frame: 1,6 and 12 months and 5 years
Stroke
all stroke and TIA
Time frame: 1,6 and 12 months and 5 years
Bleeding
Time frame: 1,6 and 12 months and 5 years
Operation site complication
Time frame: 1,6 and 12 months and 5 years
Vascular access site and access-related complication
Time frame: 1,6 and 12 months and 5 years
Acute kidney injury
Time frame: at a later date between 30 days or discharge
Event rate of permanent pacemaker insertion
Time frame: 1,6 and 12 months and 5 years
Other TAVR-related complication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Conversion to open surgery Coronary obstruction Mitral valve apparatus damage or dysfunction Cardiac tamponade Endocarditis Valve thrombosis Valve malpositioning TAV-in-TAV deployment(TAV : Transcatheter Aortic Valve)
Time frame: 1,6 and 12 months and 5 years
Prosthetic valve dysfunction
Prosthetic aortic valve stenosis Prosthesis-patient mismatch Prosthetic aortic valve regurgitation
Time frame: 1,6 and 12 months and 5 years
Event rate of composite endpoint
Device success Early safety within 30 days Clinical efficacy after 30 days defined as death, stroke, valve dysfunction or heart failure requiring hospitalization, severe dyspnea or valve dysfunction NYHA class III or IV
Time frame: 1,6 and 12 months and 5 years
Structural valve deterioration
Time frame: 1,6 and 12 months and 5 years
Change of NYHA class
the New York Heart Association (NYHA) Functional Classification
Time frame: 30 days and 1 year
Change of valve area
Time frame: 30 days and 1 year
Free from atrial fibrillation
Time frame: 1,6 and 12 months and 5 years